Johanna Friedl-Naderer Sells 900 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Johanna Friedl-Naderer sold 900 shares of Dyne Therapeutics stock in a transaction on Friday, September 4th. The shares were sold at an average price of $24.35, for a total value of $21,915.00. Following the sale, the insider directly owned 153,082 shares of the company’s stock, valued at approximately $3,727,546.70. This trade represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Johanna Friedl-Naderer also recently made the following trade(s):

• On Tuesday, September 8th, Johanna Friedl-Naderer sold 185 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $3,492.80.

Dyne Therapeutics Stock Down 16.4%

NASDAQ DYN traded down $3.97 during trading on Tuesday, reaching $20.31. 17,067,421 shares of the company’s stock traded hands, compared to its average volume of 2,151,348. Dyne Therapeutics, Inc. has a 12-month low of $11.92 and a 12-month high of $27.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of -6.10 and a beta of 1.08. The company’s 50 day simple moving average is $24.86 and its two-hundred day simple moving average is $20.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DYN. TD Cowen initiated coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Wall Street Zen lowered Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, August 17th. Raymond James Financial reiterated a “strong-buy” rating and set a $37.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday. Finally, Sanford C. Bernstein raised their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Key Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month ACHIEVE data at the World Muscle Society and AANEM meetings on September 30. The presentations will compare a pooled treated group with a matched natural-history cohort and include updated safety information. Topline data from the fully enrolled registrational expansion cohort remain targeted for Q1 2027. Dyne ACHIEVE data announcement
• Positive Sentiment: Z-basivarsen has received FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, while Dyne is advancing the program into the Phase 3 HARMONIA trial. These regulatory designations and upcoming data could provide future catalysts if clinical benefit is confirmed.
• Neutral Sentiment: Options activity was unusually high, with traders purchasing approximately 20,532 call contracts—more than 40 times the average daily call volume. This may reflect speculative positioning ahead of clinical presentations, but it does not establish a fundamental change in the company’s outlook.
• Neutral Sentiment: Several insiders, including CEO John Cox, Chief Medical Officer Douglas Kerr and Chief Commercial Officer Johanna Friedl-Naderer, reported small stock sales. The filings state that the transactions were made to cover tax withholding obligations from vested equity awards, reducing their negative significance.
• Negative Sentiment: Investor sentiment was pressured after a competing DM1 drug reportedly failed in a Phase 3 trial. The result may have increased concern about the difficulty of demonstrating meaningful clinical benefit in DM1 and raised the risk profile ahead of Dyne’s own data release. DM1 rival trial news
• Negative Sentiment: No company-specific negative clinical result was confirmed in the reports. However, the absence of new efficacy data today, combined with uncertainty surrounding the upcoming one-year results and the delay until Q1 2027 for registrational-cohort topline data, left DYN vulnerable to profit-taking and risk reduction. Dyne share decline report

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DYN. Nykredit A S acquired a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $113,000. California State Teachers Retirement System increased its stake in Dyne Therapeutics by 2,049.2% during the 2nd quarter. California State Teachers Retirement System now owns 3,001,615 shares of the company’s stock valued at $66,666,000 after purchasing an additional 2,861,952 shares in the last quarter. Moore Capital Management LP raised its holdings in shares of Dyne Therapeutics by 288.2% in the second quarter. Moore Capital Management LP now owns 305,794 shares of the company’s stock worth $6,792,000 after buying an additional 227,029 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Dyne Therapeutics during the second quarter worth $222,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Dyne Therapeutics during the second quarter worth $5,448,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.